volrustomig
1 product
5 abstracts
Abstract
GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.Org: Chang Gung Memorial Hospital at Linkou and Chang Gung University, Seoul National University Graduate School, AstraZeneca Global R&D (China) Co., AstraZeneca Pharmaceutical Co.,
Abstract
eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).Org: Head and Neck Medical Oncology Unit, Department of Oncology and Hemato-Oncology University of Milan,
Abstract
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.Org: Hospital del Mar-CIBERONC, Institute Curie,
Abstract
GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers.Org: NTUH Cancer Hospital, B2F Samsung Comprehensive Cancer Center, Jiangsu, China, Shatin, Hong Kong,
Abstract
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).Org: Virginia Cancer Specialists, AstraZeneca, Bloomberg–Kimmel Institute for Cancer Immunotherapy,
Product
MEDI5752